Loading
A small company near Oxford that designs medicines to point the immune system at new targets found only on diseased cells, for solid cancers and some autoimmune diseases.
T-Cypher Bio states that it develops immune-engaging medicines against novel disease-specific targets for cancer and autoimmune disease, with a pipeline across a range of solid tumours and selected autoimmune diseases, built on proprietary platforms that combine laboratory and computational methods (T-Cypher Bio website). Its registered address is Barton House, the Quadrant, Abingdon (T-Cypher Bio website). Its team page says that a number of inventions from the University of Oxford laboratory of its scientific co-founder have been licensed to the company (T-Cypher Bio, About us).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/